With the recent approval of Tecvayli™ and other bispecific antibodies, along with the ongoing R&D efforts for evaluating the potential of such candidates against various disease indications, this segment of the pharmaceutic industry has garnered significant interest of stakeholders…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.